Skip to search formSkip to main contentSkip to account menu

gemigliptin

Known as: 1-((2S)-2-Amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one 
An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Ninhydrin Based Visible Spectrophotometric Determination of Gemigliptin
A simple method is described to determine the amount of gemigliptin in bulk and tablet formulation by visible spectrophotometry… 
2018
2018
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study
The long‐term safety and efficacy of gemigliptin was evaluated in the present extension study after a 12‐week study during a 40… 
2018
2018
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells
PurposeThe influence of the dipeptidyl peptidase-IV inhibitor, gemigliptin alone or in combination with metformin on survival… 
2018
2018
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
PurposeThe influence of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the histone deacetylase… 
2018
2018
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
Background and Objectives To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4… 
2017
2017
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study)
The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with… 
2017
2017
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are widely used antihyperglycemic agents for type 2 diabetes mellitus. Recently… 
2017
2017
Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes
We aimed to investigate the effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on postprandial lipoprotein levels and… 
2015
2015
Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial
BackgroundCisplatin is a potent chemotherapeutic agent, but its nephrotoxicity, which results in acute kidney injury (AKI), often… 
2014
2014
Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)